ReviewNature reviews. Clinical oncology2021
Tumour budding in solid cancers.
Review in Nature reviews. Clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 212 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
212 citing papers in PubMed, 7 syntheses or guidelines pooled it, 352 citations in OpenAlex.
- Accumulating evidence from meta-analyses of prognostic studies on oral cancer: towards biomarker-driven patient selection.BMC cancer · 2024Pooled it
- SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- The relationship between tumor budding and survival of patients with breast cancer: A meta-analysis.Biomolecules & biomedicine · 2024Pooled it
- Tumor Budding and Poor Prognosis in Oral Cancer: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2023Pooled it
- Tumor budding and the prognosis of patients with metastatic colorectal cancer: a meta-analysis.International journal of colorectal disease · 2023Pooled it
- Emerging histopathologic markers in early-stage oral tongue cancer: A systematic review and meta-analysis.Head & neck · 2022Pooled it
- Tumor Budding as a Marker for Poor Prognosis and Epithelial-Mesenchymal Transition in Lung Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Impact of stromal maturity and proportion on prognosis and immune landscape in colorectal cancer.Annals of medicine · 2026Article
- T1 colorectal cancer: determinants of lymph node metastasis, survival patterns, and risk-adapted management.Updates in surgery · 2026Review
- Local Recurrence After Pancreatic Cancer Resection: A Multidisciplinary Review of Risk Factors and Potential Causes, Diagnostic Innovations, Emerging Therapeutic Frontiers, and Prevention Strategies.Current treatment options in oncology · 2026Review
- Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression.British journal of cancer · 2026Article
- Impact of tumor budding on recurrence risk prediction in stage I-III colorectal cancer: a Swedish cohort study.American journal of clinical pathology · 2026Article
- Tumor Vascular Area Quantification Predicts Survival Outcomes in Oral Squamous Cell Carcinoma.Oral diseases · 2026Article
- CLDN-2 Expression Aligns with Invasion-Associated Epithelial Remodeling in Colorectal Cancer.Cancers · 2026Article
- Preoperative prediction of tumor budding grade in rectal cancer by combining APT histogram analysis and ADC MRI.European radiology experimental · 2026Article
- Preoperative synthetic magnetic resonance imaging-based biomarkers for predicting tumor budding of rectal cancer.BMC medical imaging · 2026Article
- Digital Pathology and the AI-Based Quantification of the Tumor Microenvironment in Gastrointestinal Cancer: From Tumor Budding and Tumor-Infiltrating Lymphocytes to Tertiary Lymphoid Structures.International journal of molecular sciences · 2026Review
- Integrating Clinical and Molecular Insights: CTPS1 as a Key Biomarker of Tumor Progression and Prognosis in Colorectal Adenocarcinoma.Applied immunohistochemistry & molecular morphology : AIMM · 2026Article
- A Soft Matrix Microenvironment Promotes Laterally Spreading Tumors via Oxidative Phosphorylation-Dependent Cell Adhesion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
152 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumour budding is an emerging prognostic biomarker in colorectal cancer (CRC) and other solid cancers. Tumour buds are usually defined as isolated single cancer cells or clusters of up to four cancer cells located at the invasive tumour front. The prognostic value of tumour budding is now supported by a large body of evidence, whereas the utility of this phenotype as a predictive biomarker remains under investigation. The application of tumour budding indices in clinical practice requires a standardized scoring system that can be tailored to specific tumour types and clinical scenarios. In the context of CRC, tumour budding can be assessed according to the method agreed at the International Tumour Budding Consensus Conference (ITBCC) in 2016. Using the ITBCC scoring system, tumour budding is an independent predictor of lymph node metastasis in patients with pT1 CRC and of unfavourable survival in patients with stage II colon cancer. Regardless of the clinical scenario or tumour type, the assertion that 'the more tumour buds, the worse the clinical outcome' applies. In this Review, we provide an overview of tumour budding in solid cancers, highlighting the molecular and biological aspects of this phenomenon, including its associations with epithelial-mesenchymal transition and features of the tumour microenvironment. We also describe the available evidence demonstrating the value of tumour budding as a biomarker across various solid cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.